PU.1, a member of the ets family of transcription factors, is upregulated during haematopoietic development, and is specifically expressed in mature myeloid and B cells ([Klemsz *et al*, 1990](#bib6){ref-type="other"}; [Hromas *et al*, 1993](#bib5){ref-type="other"}; [Chen *et al*, 1995](#bib1){ref-type="other"}). The crucial and exclusive role of PU.1 in haematopoietic differentiation is established by the following observations. A number of genes are regulated by PU.1 in both myeloid and B-cell lineages, including those encoding colony-stimulating factor receptors and immunoglobulin subunits ([Shin and Koshland, 1993](#bib16){ref-type="other"}; [Zhang *et al*, 1994](#bib19){ref-type="other"}; [Hohaus *et al*, 1995](#bib4){ref-type="other"}; [Smith *et al*, 1996](#bib17){ref-type="other"}). Overexpression of PU.1 early in erythroid development blocks erythroblast differentiation and induces murine erythroleukaemia ([Moreau-Gachelin *et al*, 1988](#bib9){ref-type="other"}, [1996](#bib10){ref-type="other"}; [Paul *et al*, 1991](#bib13){ref-type="other"}). Gene targeting of PU.1 results in the failure of development of mature myeloid cells, and the addition of PU.1 site-containing competitor oligonucleotides to human CD34^+^ bone marrow cells inhibits *in vitro* myeloid colony formation ([Voso *et al*, 1994](#bib18){ref-type="other"}; [Fisher *et al*, 1998](#bib3){ref-type="other"}). In addition, mice with a disruption in both alleles of the PU.1 locus were found to have severe defects in the development of both myeloid and lymphoid cells, characterised by the absence of macrophages and B cells, and the delayed appearance of neutrophils ([Scott *et al*, 1994](#bib15){ref-type="other"}; [McKercher *et al*, 1996](#bib7){ref-type="other"}).

Although the role of PU.1 in normal haematopoiesis has been broadly investigated, its significance for leukaemogenesis is less known. Recently, it was shown that an 80% reduction of PU.1 expression is sufficient to cause acute myeloid leukaemia (AML) in mice ([Rosenbauer *et al*, 2004](#bib14){ref-type="other"}). Our group has reported that heterozygous *PU.1* mutations are observed in some AML patients ([Mueller *et al*, 2002](#bib12){ref-type="other"}). Finally, we demonstrated that PU.1 expression is critically suppressed by the PML-RARA fusion protein, the hallmark of AML-M3 patients ([Mueller *et al*, 2006](#bib11){ref-type="other"}). These findings point to a role of *PU.1* for both normal haematopoietic differentiation and leukaemogenesis.

With regard to the finding of PU.1 mutations in some AML patients and to the role of *PU.1* in B-cell development, we hypothesised that B-cell acute lymphoblastic leukaemia (B-ALL) might similarly harbour genomic abnormalities in the *PU.1* gene. Therefore, we screened a collection of 62 B-ALL patients for *PU.1* mutations.

PATIENTS AND METHODS
====================

Analysis of mutations of the PU.1 gene was performed in 45 healthy volunteers (bone marrow donors) and 62 patients with B-ALL. Forty-six childhood B-ALL patients were treated on one of two consecutive Dana Farber Cancer Institute childhood ALL protocols (85-001 or 87-001), and 16 adult B-ALL patients were treated on the French Intergroup LALA 94 protocol in Bern, Switzerland. The 46 childhood ALL patients have previously been presented for unrelated purposes ([McLean *et al*, 1996](#bib8){ref-type="other"}). Patient characteristics are presented in [Table 1](#tbl1){ref-type="table"}. The male/female ratio was 40/22 among the ALL patients and 29/16 for the healthy volunteers, and the age range was 1--62 years (median 9 years) for the ALL patients and 16--78 years (median 29 years) for the control group.

The patient samples were collected at the time of diagnosis before initiation of treatment and after having obtained informed consent. Mononuclear cells were isolated from bone marrow samples by Ficoll density gradient centrifugation and cryopreserved in liquid nitrogen until molecular analysis. Detection of PU.1 mutations was made on genomic DNA extracted from bone marrow samples. Polymerase chain reaction (PCR) analysis using exon-specific primers was performed of the five PU.1 exons comprising the entire coding region of the PU.1 gene. Exon-specific primers were designed from the sequence in GenBank (AC019059 and AC01841; [Supplementary Table 2](#sup1){ref-type="other"}). All primers were selected to include the exon/intron boundaries to exclude splice junction mutations. Analysis of the PCR products was described previously ([Mueller *et al*, 2002](#bib12){ref-type="other"}). Briefly, PCR products were electrophoresed on 1% agarose gels, gel-purified (Qiagen, Valentia, CA, USA), and sequenced using BigDye Terminators and AmpliTaq FS (Applied Biosystems, Foster City, CA, USA).

RESULTS AND DISCUSSION
======================

We screened leukaemic cells from patients with B-cell ALL for mutations in the coding region of the PU.1 gene by direct sequencing of exon-specific PCR products. We observed no sequence variants in the coding sequence in 62 ALL patients (90% upper confidence bound of 3.64%) and in 45 healthy volunteers (90% upper confidence bound of 4.98%).

The absence of detectable PU.1 mutations in ALL patients is in contrast to the results of our previous report where we detected mutations in a large series of AML patients ([Mueller *et al*, 2002](#bib12){ref-type="other"}). In nine of 126 AML patients (7%), mutations of the PU.1 gene were identified, with seven of these nine AML patients having heterozygous mutations and two having both alleles affected by different mutations. Seven of the PU.1 mutations in AML patients affected the DNA-binding domain, and we demonstrated that those PU.1 mutations were deficient in DNA binding to and transactivation of the macrophage colony-stimulating factor receptor promoter, a direct PU.1 target gene. In addition, these mutations decreased the ability of PU.1 to synergise with interacting proteins such as AML1 or c-Jun to activate PU.1 target genes. Finally, some of these mutations have lost the ability of the PU.1 wild-type protein to induce terminal differentiation of PU.1-deficient progenitor cells.

Our results suggest that, unlike in AML, PU.1 is not inactivated by mutations in patients with ALL. Assuming a frequency of mutational events similar to that seen in AML patients (7%), we would expect to detect 4.34 mutations among the 62 ALL patients screened. Because the number of patients of each ALL subtype in our series is limited, we cannot exclude a low incidence of mutations in some specific subtypes of ALL. In addition, because we used exon-specific primers and DNA as a template, we cannot rule out the presence of some mutations not detectable by this PCR approach, for example, heterozygous deletions spanning one or several exons.

The apparent absence of PU.1 mutations in ALL in contrast to the presence of PU.1 mutations in some AML patients could be linked with the function of the PU.1 protein. It was recently hypothesised that differing concentrations of the PU.1 protein regulate the development of B-lymphocytes as compared with macrophages ([DeKoter and Singh, 2000](#bib2){ref-type="other"}): A low concentration of PU.1 protein (one-fifth to one-seventh as much) was proposed to induce a B-cell fate, whereas a high concentration would promote macrophage differentiation and block B-cell development. It is noteworthy that wild-type macrophages express higher levels of PU.1 protein than their pro-B counterparts ([Chen *et al*, 1995](#bib1){ref-type="other"}). This suggests that absence or reduction in the amount of wild-type PU.1 protein might have different consequences for myeloid and lymphoid development. Whereas PU.1 mutations might contribute to the malignant phenotype in myeloid cells, a mutant PU.1 peptide in lymphoid cells might lack consequences in terms of leukaemogenesis.

External data objects {#sup1}
=====================

###### Supplementary Table 2
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###### 

Clinical characteristics of patients studied

                            **(*n*)**
  ------------------------ -----------
  *Protocol*               
   85-001                      22
   87-001                      24
   LALA 94                     16
                                 
  *Age*                    
   Range (years)              1--62
   Younger than 20 years       46
   20 years or older           16
                                 
  *Immunophenotype*        
   B-cell                      62
   T-cell                       0
                                 
  *CNS involvement*        
   No                          57
   Yes                          5
                                 
  *Sex*                    
   Male                        40
   Female                      22
                                 
  *WBC*                    
   \<20 000/*μ*l               27
   \>20 000/*μ*l               35
                                 
  *Cytogenetics*           
   t(12;21)                    11
   t(9;22)                      5
   t(4;11)                      2
   t(1;19)                      1
   Complex                     11
   Normal                      15
   Others                      13
   NA                           4

CNS=central nervous system; NA=not available; WBC=white blood cell count.

Clinical characteristics at the time of diagnosis of the 62 ALL patients are shown. Patients were enrolled on one of two consecutive Dana Farber Cancer Institute childhood ALL protocols (85-001 and 87-001) or on the French Intergroup LALA 94 protocol for adult ALL patients.
